THE ROLE OF CHANGES IN THE HIPPOCAMPAL SEROTONIN TRANSPORTER IN THE PATHOLOGY OF SCHIZOPHRENIA
Funder
National Health and Medical Research Council
Funding Amount
$340,317.00
Summary
Schizophrenia is a serious mental illness that affects approximately 1% of the Australian population. The cause of the illness remains unknown but many lines of evidence suggest that changes in the function of a chemical neurotransmitter, serotonin, are involved in the disease process. We have shown a change in the serotonin transporter, a critical component of the brain which controls the actions of serotonin, in the an area of the brain called the hippocampus in subjects with schizophrenia. Th ....Schizophrenia is a serious mental illness that affects approximately 1% of the Australian population. The cause of the illness remains unknown but many lines of evidence suggest that changes in the function of a chemical neurotransmitter, serotonin, are involved in the disease process. We have shown a change in the serotonin transporter, a critical component of the brain which controls the actions of serotonin, in the an area of the brain called the hippocampus in subjects with schizophrenia. This proposal seeks to elucidate the mechanisms by which a change in the serotonin transporter may affect other important molecules in the hippocampus. In addition, we will continue our research designed to assess the usefulness of the 5,7-dihydroxytryptamine treated rat as a possible tool for the study of changes in the serotonin transporter.Read moreRead less
Role Of Brain Serotonin In Animal Models Of Schizophrenia
Funder
National Health and Medical Research Council
Funding Amount
$175,550.00
Summary
There is increasing evidence that deficiencies in the release of a brain chemical called serotonin play an important role in the development of schizophrenia. Post-mortem studies have shown changes in the levels of 'receptors' (keyholes for messenger chemicals in the brain) for serotonin in schizophrenia. In addition, in the treatment of schizophrenia, the more recently introduced 'atypical' antipsychotic drugs are superior to the more traditional 'typical' antipsychotics in terms of efficacy an ....There is increasing evidence that deficiencies in the release of a brain chemical called serotonin play an important role in the development of schizophrenia. Post-mortem studies have shown changes in the levels of 'receptors' (keyholes for messenger chemicals in the brain) for serotonin in schizophrenia. In addition, in the treatment of schizophrenia, the more recently introduced 'atypical' antipsychotic drugs are superior to the more traditional 'typical' antipsychotics in terms of efficacy and side-effect profile. Typical antipsychotic drugs act mainly through blockade of receptors for a brain chemical called dopamine. Atypical drugs appear to have additional actions, in particular blocking the effect of serotonin in the brain. This evidence is mostly circumstancial, relying to a large extent on biochemical analysis of brain regions and 'receptors' on which antipsychotics MAY act. It is currently unclear exactly how and where in the brain changes in serotonin activity influence behavioural processes causing schizophrenia. It is also unclear how and where typical and atypical antipsychotic drugs interact with the role of serotonin in schizophrenia. In this project we intend to inactivate specific parts of the serotonin system of otherwise intact, freely moving rats. Using behavioural observation methods relevant for schizophrenia, we will analyze if and how these interventions influence the behaviour of these rats. The results can have important implications for our fundamental understanding of the involvement of serotonin in the brain in schizophrenia.Read moreRead less
Headache Prophylaxis By Cortico-brainstem Mechanisms
Funder
National Health and Medical Research Council
Funding Amount
$616,437.00
Summary
In this project we hope to discover the cause of migraine headache. Many triggers lead to migraine, but we do not know how. We believe the triggers produce a defect in pain control by the brainstem, which normally keeps sensation from the head below the pain threshold. In migraine, trigger factors acting high in the brain open a pain control gate lower in the brain, producing a migraine headache. If we can prove this, we can develop therapies that will prevent migraine before it starts.